Extracellular Particle Release After BBB Opening Predicts Glioblastoma Response to Paclitaxel

---

A new study published in Nature Communications reports a powerful strategy to monitor glioblastoma therapy using an ultrasound-enabled liquid biopsy platform. By transiently opening the blood–brain barrier during chemotherapy, researchers captured tumor-derived extracellular particles in the bloodstream and showed that their molecular signatures predict treatment response.

Using an advanced microfluidic capture system, the team demonstrated that circulating tumor particles released after barrier opening provide a dynamic, minimally invasive readout of tumor biology offering a potential real-time biomarker to guide precision therapy in one of the most treatment-resistant brain cancers.

This interdisciplinary effort was co-led by senior authors Sunitha Nagrath and Adam M. Sonabend (Northwestern University Feinberg School of Medicine, Chicago), whose collaboration began after meeting at the last BIBC Symposium — a scientific exchange that catalyzed this translational breakthrough.

The work establishes a clinically actionable framework for tracking glioblastoma response through blood-based biomarkers, advancing the integration of bioengineering, neuro-oncology, and precision medicine.